262 related articles for article (PubMed ID: 31376566)
1. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
[TBL] [Abstract][Full Text] [Related]
2. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
Yang L; Zhou F; Zhuang Y; Liu Y; Xu L; Zhao H; Xiang Y; Dai X; Liu Z; Huang X; Wang L; Zhao C
Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
[TBL] [Abstract][Full Text] [Related]
3. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
4. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
Alsfouk A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
[TBL] [Abstract][Full Text] [Related]
10. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Wang X; Chen F; Gou S
Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.
Bistrović A; Krstulović L; Harej A; Grbčić P; Sedić M; Koštrun S; Pavelić SK; Bajić M; Raić-Malić S
Eur J Med Chem; 2018 Jan; 143():1616-1634. PubMed ID: 29133046
[TBL] [Abstract][Full Text] [Related]
12. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
15. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC.
He L; Li D; Zhang C; Bai P; Chen L
Bioorg Med Chem Lett; 2017 Sep; 27(17):4171-4175. PubMed ID: 28734581
[TBL] [Abstract][Full Text] [Related]
17. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
[TBL] [Abstract][Full Text] [Related]
18. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
[TBL] [Abstract][Full Text] [Related]
19. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
[TBL] [Abstract][Full Text] [Related]
20. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
